Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. - Wikidata - wikimedia - TriplyDB

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

http://www.wikidata.org/entity/Q37372794

about

Role of HLA Adaptation in HIV Evolution Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection Profiling immunity to HIV vaccines with systems biology Progress and prospects: immune responses to viral vectors IL-33 induces nuocytes and modulates liver injury in viral hepatitis.Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality Adenoviral vectors as novel vaccines for influenza.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers.Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.HIV-1 vaccine development after STEP.Novel directions in HIV-1 vaccines revealed from clinical trials Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.Novel adenovirus vector-based vaccines for HIV-1.New approaches to design HIV-1 T-cell vaccines Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine Novel vaccine vectors for HIV-1.Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1.Lessons drawn from recent HIV vaccine efficacy trials.Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.A Novel High-Throughput Screening Assay to Identify Inhibitors of HIV-1 gp120 Protein Interaction with DC-SIGN.Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.Evolutionarily conserved T-cell epitopes on FIV for designing an HIV/AIDS vaccine HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Sexual risk behaviors, circumcision status, and preexisting immunity to adenovirus type 5 among men who have sex with men participating in a randomized HIV-1 vaccine efficacy trial: step study Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.Risk of immunodeficiency virus infection may increase with vaccine-induced immune response.Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).DNA-based HIV vaccines do not induce generalized activation in mucosal tissue T cells.

P2860

Q26772713-59216D79-D89F-4965-8256-E5CE82E8FF6A Q27001897-8DEB7C65-734F-4E0A-989A-8581ECE36EB8 Q27010629-9A02736B-E926-4C3D-8D44-4EC6C6673BA5 Q28264531-DFB694F1-DC8E-4EFA-9EF8-A4EF8A8E6F1C Q28588039-4E664F43-A0F6-4394-974E-9134E4C81211 Q28730757-4B2A0BEE-989A-4499-9291-DF59EFEC4C68 Q28741103-9A862996-5C1F-4AEF-BE7A-05C66E303017 Q28744027-98E45F8F-2D95-4FB3-B095-D683BB14AE85 Q30370445-B0F93334-533F-472E-9AE2-1951A19CF73A Q30382097-5485CD0A-8E84-4B22-8893-A0B37A7E0E96 Q33565035-27C1CAC3-3B06-4600-B5B4-4B909EC61F2F Q33601808-B218A5CE-AA59-4272-AB4D-29E405834F39 Q33642318-33FF53E8-F46F-4AA9-B760-D406F5A8E593 Q33645528-4AC75A2C-9621-41C8-86ED-0A6AA1FBA85A Q34120780-A55B61D8-3D16-4EBD-AFA7-008CC9EE9001 Q34178208-37825D0C-DE7E-4C85-A799-12F31CBCBEAE Q34257640-6FCE56FC-FA22-4627-9F5C-7EC61695718C Q34274849-96F30BB3-8057-4F29-9D2B-B517A81CB3C1 Q34373275-84F63748-9609-4777-9217-77B82D3C6A12 Q34541191-E28DFBF9-7409-43D2-A48F-5BA855BAAFE9 Q34673391-A28305DC-1C17-44D3-BD69-B128604D1920 Q34789269-3657FA1D-22C5-4B91-9BC5-BC227DA4295B Q34816639-851CDBAF-310A-4779-A1DD-20C1B936DB58 Q35055188-28B6BEF3-9A66-4BE2-912C-17643D666B31 Q35382338-AD0B3E21-D69A-4388-8D94-30DB39AFC9F0 Q35553053-EC1EA1FE-208E-4AFF-844E-FE431F73ECD3 Q35640645-5BA69B2B-03A6-4E87-B5B7-13BDE5DB6B38 Q35666180-FDE73112-D4D4-433A-A8D0-71EFC0395754 Q35709133-85D1E136-0D8F-4375-B80B-FFF5A7F89902 Q35745815-356EF95B-73CE-411F-810C-7FC95F0AAB48 Q35980530-ECDB55BF-B45B-4E3D-A415-95FE58C80707 Q36009232-6C68F1FC-4044-4B9A-9EAE-3A7F56BA0C38 Q36084253-3E14A6A4-96DC-409C-A842-C0AF2BC2B604 Q36145561-B4D99B5D-7BD6-42C8-9171-FA2A8820B696 Q36154059-9F867485-7645-408D-901B-0BB2A5A57FD9 Q36276187-753E7DDA-6B04-44AB-AA2A-5975E95F70F7 Q36276637-3119D6A7-DCCA-4612-81FE-ED82FAF386B5 Q36483435-9D6BF13A-51A6-4A60-8BE7-F122BFA95CCD Q36495587-E9C6A828-9190-4D5E-A41A-75BB9E1093D9 Q36694851-5E248A78-32DB-4592-9FFD-A4C6CC48DC26

P2860

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

http://www.wikidata.org/entity/Q37372794

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.

@en

Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.

@nl

type

label

Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.

@en

Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.

@nl

prefLabel

Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.

@en

Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.

@nl

P1433

Q37372794-80AFF782-3039-455F-B93E-506B4AAEE76F

P1476

Q37372794-C166728B-1699-4D43-822D-15AAE6903814

P2093

Q37372794-19044442-4B4B-4DF2-AD3D-0852DB7D53E1

Q37372794-1B074DA5-218A-4FED-BDB7-4B481A979537

Q37372794-1B54F891-443F-401A-9C74-7929BD6A48CC

Q37372794-232E05FC-7424-41B6-B04A-852CFCF24FCE

Q37372794-2CA3E4CD-0E02-46BB-93A7-2751A11F162D

Q37372794-32E66E5D-EFB0-449D-847E-C76BC655F0FF

Q37372794-4770C95C-D4CD-4BCF-8848-05FCE998AEAB

Q37372794-4B56178A-AA97-48D2-B5BE-984848586371

Q37372794-90E93E77-D260-4351-BD45-6A0AF26A8E80

Q37372794-9E0DDC2D-8159-4F2E-AB26-071606AAEA24

P2860

Q37372794-14459828-A2E9-4332-80F1-7301F826A3A4

Q37372794-18B63A87-20D0-4EC9-9D2B-E92BCD85695C

Q37372794-1E063517-1E50-4F03-8ECA-17A5645A23CD

Q37372794-22B6FE27-0F30-4455-B93A-F1A80300A678

Q37372794-53B15791-3D4A-460E-9655-E826F98E6A7D

Q37372794-74FD8BCA-D7FF-4285-914D-E77F7B2E2E1E

Q37372794-7658057F-3FA3-4A2C-992C-AEFF25A95834

Q37372794-88095391-393B-44FD-989B-90B6CE66B46A

Q37372794-9485E275-EC76-4FD6-B313-F01629D41ABA

Q37372794-AED296EC-5C31-45B1-8457-A0DA943580AA

P2888

Q37372794-3D445463-0304-44FD-8E2C-34E2B6ADA198

P304

Q37372794-BE8D185E-1DBF-4B34-B174-078855346EE4

P31

Q37372794-34A282F3-757B-4A47-A87B-7DD2B890282A

P356

Q37372794-EEE334BF-8DDA-43DE-80A8-22500BBBDD50

P407

Q37372794-9EA5BF56-4ABC-4952-9C54-1AADF48371E5

P433

Q37372794-26C3BAB9-3E2B-4FB0-862C-9623659824C2

P478

Q37372794-9FD55764-DD4B-41DE-8691-808A2E157564

P50

Q37372794-925BCA24-5101-4448-8D51-E2FD1E332808

P577

Q37372794-0E8A7088-DD1F-4E20-9F0C-773D3A0299CA

P5875

Q37372794-F99A3E60-4896-4FEF-A168-02555EFA23E3

P698

Q37372794-8B57C19A-9D88-45DC-93BC-C21F75C21817

P921

Q37372794-3D26B4C4-EDA7-4449-8CB7-1596B80A9C66

Q37372794-538B0E4B-03CF-4769-A6EA-496B9B490AD4

Q37372794-CE80D977-1C59-4737-8F2E-A48FA85DD706

P932

Q37372794-3705C236-DCF4-4EA3-B07C-74327D88BD2F

P356

P1433

Nature Medicine

P1476

Adenovirus-specific immunity a ...... 1 vaccine candidate in humans.

@en

P2093

Dan H Barouch

http://www.w3.org/2001/XMLSchema#string

Danilo R Casimiro

http://www.w3.org/2001/XMLSchema#string

Jinyan Liu

http://www.w3.org/2001/XMLSchema#string

Joern E Schmitz

http://www.w3.org/2001/XMLSchema#string

John W Shiver

http://www.w3.org/2001/XMLSchema#string

Kara L O'Brien

http://www.w3.org/2001/XMLSchema#string

Michael N Robertson

http://www.w3.org/2001/XMLSchema#string

Michael R Betts

http://www.w3.org/2001/XMLSchema#string

Michelle A Lifton

http://www.w3.org/2001/XMLSchema#string

Natalie A Hutnick

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells

Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

P2888

P304

873-875

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.1991

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26684631

http://www.w3.org/2001/XMLSchema#string

P698

19620961

http://www.w3.org/2001/XMLSchema#string

P921

P932

2756115

http://www.w3.org/2001/XMLSchema#string